… the Cochrane risk-of-bias tool for randomized trials (RoB 2; … evaluate the efficacy and safety
of daratumumab in patients … the control group, the combined daratumumab group had better …

… Quality was assessed by the Cochrane risk-of-bias method. … relapsed or refractory SRMM,
with significant PFS benefit in the daratumumab group reported in the CASTOR (HR, 0.26; 95…

… The heterogeneity among these trials was evaluated using Cochrane chi-squared test
and quantified with the I 2 statistic. All meta-analyses were undertaken with Stata ver. 12.0 …

… compared the efficacy and toxicity of daratumumab to other … , the efficacy of ORR or at least
VGPR between the group is … , the efficacy of ORR or at least VGPR between the group is …

… The same reviewers extracted the data independently using standardized data collection …
We assessed the risk of bias using the Cochrane RoB2 tool which assess the risk of bias in …

… based on Cochrane's handbook 18 … daratumumab compared to the control group. On the
other hand, lymphopenia and neutropenia occurred more frequently in the daratumumab group …

… and the Cochrane Library was conducted to identify and then assess RCTs of treatments
for … that had investigated the efficacy and safety of other treatment options considered to be …

… of the included trials using the Cochrane Q statistic and I 2 … daratumumab group than in
the control group, regardless of patient subgroup. Regarding the safety profile of daratumumab …

… in Daratumumab treatment group while 684 patients in control … multiple myeloma (MM) [2].
METHODS AND METHODOLOGY This meta-analysis was conducted according to Cochrane …

… We conducted a systematic literature review in line with Cochrane … mixed-treatment
comparison methods to provide relative efficacy estimates. Our analyses suggest that daratumumab-…